Tesaglitazar
Tesaglitazar is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of Diabetes [mellitus type 2|type 2 diabetes].
The drug had completed several phase III [clinical trial]s, however in May, 2006 AstraZeneca announced that it had discontinued further development.
Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARγ [coactivator 1-α] and sirtuin 1.